User login

We offer our registered users tailored information, free online courses and exclusive content.

You have an old EXCEMED account ...

Our platform has been renewed. All users registered at any of the old websites are kindly requested to reset their password. Why is this?

... or you lost your password?

Search results

  1. Management of Pre-diabetes in the Asia-Pacific region

    ... of ≥150 minutes per week. 5 The ADA states that metformin therapy for prevention of type 2 diabetes may be considered in ... the 2015 Ministry of Health (MOH) guidelines state that metformin (as the preferred first-line oral anti-diabetic agent) should be ...

  2. 2017 Hot topics in cardiometabolism: an interactive update

    ...     Q&A 10.40     Coffee break Session II: Metformin: 60 years of an evergreen molecule Chairs: G. Brenta (Argentina), ... J.P. Lopez-Jaramillo (Colombia) 11.00   L3  metformin: mechanism of action and cardiovascular benefits   VIDEO LECTURE ...

  3. Congress Report: 17th American Diabetes Association (ADA) meeting

    ... (SGLT2)-inhibitors in the CVD REAL study 3 and metformin in the REMOVAL study. 4 The DEVOTE study , comparing the ... agents. The REMOVAL trial (Reducing with Metformin Vascular Adverse Lesions) was presented by its lead investigator ... with type 1 diabetes and increased CV risk to daily metformin 1000 mg twice daily or placebo as adjuncts to insulin. All patients ...

  4. EASD conference 2013: Highlights from the European Society for the Study of Diabetes meeting 2013

    ... complications in the long-term. In general, the inclusion of metformin in the therapeutic strategy gave the highest efficacy in reducing ... for the proper selection of therapeutic combinations. Metformin remains the base, with TZDs and DPP4 inhibitors added in presence ...

  5. Scientific Highlights: 2015 Asia Pacific conference on cardiometabolic diseases management

    ... treatment is also important; there is mounting evidence that metformin is beneficial for HF, whereas thiazolidinediones are thought to ... Medications approved for obesity, e.g., orlistat, as well as metformin, acarbose and pioglitazone have proven effective in slowing ...

  6. Scientific Highlights: 2016 Latin American conference on cardiometabolic diseases management: health emergencies in focus

    ... delaying its development. Oral antidiabetes therapy (e.g. metformin) and statin treatment, should be secondary actions, following ... interventions are required for T2DM prevention, metformin (biguanide) remains the drug of choice, as recommended by the ... its use for diabetes prevention to be off-label. Metformin improves insulin sensitivity and reduces fasting or postprandial ...

  7. Highlights from the 18th American Diabetes Association meeting (ADA), Orlando, USA, June 22–27th 2018

    ... were randomly assigned to receive either 12 months of metformin or 3 months of the insulin glargine followed by 9 months of metformin. After 12 months, medications were discontinued for a 3-month washout ...

  8. Congress report: 72nd American Diabetes Association meeting

    ... A1C levels in the normal range) after two to four months on metformin during the pre- randomization period were more likely to maintain ... than 6.1 percent after the first few months of treatment on metformin. This suggests that some children (about half in the study), at ...

  9. EASD Conference 2012: Highlights from the European Society for the Study of Diabetes-EASD 2012

    ... great importance and should be observed continuously, while metformin remains the first-line therapy for all diabetics, even in cases of ... a mild or no increase, but not a decrease. On the contrary, metformin seems to have a neutral or a protective effect on cancer risk ...

  10. Recommended reading – key published papers from 2017

    ... and management of obesity.   Marshall S. 60 years of metformin use: a glance at the past and a look to the future.  Diabetologia ... a common theme is that robust evidence is lacking for metformin use in many of these conditions, threatening the chance of this drug ...

Pages